Frans Badenhorst

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuropro-tective effects. In clinical trials, DMF was associated with reduced white blood cell and absolute lymphocyte counts. Current US prescribing(More)
  • 1